Summary Seven of eight rhesus monkeys (RM) coinfected with simian immuno deficiency virus (SIV) and My cobacterium leprae harboured acid-fast bacilli (AFB) at sites of dermal inoculation and/or at disseminated sites at times of humane sacrifice (up to 270 days post-M. leprae inoculation) due to SIV-induced debilitation or, in one long term survivor's case, to date over 3 years post-M. leprae inoculation. Detectable AFB were cleared in biopsies of inoculation sites of RM inoculated with M. leprae alone after 63 days postinoculation; these sites have, so far, remained AFB-negative, thereafter.
Introduction
Interactions between the AIDS virus and M. Jeprae
It is well established that human immunodeficiency virus (HIV)-positive patients are rendered more susceptible than virus-negative persons to secondary infections with
My cobacterium tuberculosis l -3 and other opportunistic infectious agents. SIV is very similar to HIV-2 and causes AIDS in RM with fatal symptoms and sequelae essentially identical to AIDS in humans, e.g. lymphadenopathy, diarrhoea, destruction of CD4+ T-cells, a decreased blood MNC CD4:CD8 ratio, and increased susceptibility to lymphomas and opportunistic infections. 4 -8 We reported that RM infected with both SIV and M. leprae are more susceptible to clinical leprosy than RM infected with M. leprae alone. 4 , 5 This observation led us to predict an increase in the incidence of leprosy worldwide, secondary to the AIDS pandemic.
4 This prediction has not been consistently confirmed to date, however, for unknown reasons.
-14
Data from one field study was consistent with our observation of an increased risk of leprosy in HIV -positive individuals, finding a 4'6-odds ratio in increased multibacillary (MB) leprosy risk (and 8·3 for tuberculosis risk) among HIV-positive patients in Tanzania. 9 Other reports failed to find a significant association in the aggregate populations studied, IO -14 but two of these studies found a significantly increased leprosy relapse rate among HIV -positive African leprosy patients after completion of antileprosy chemotherapy. IO , 14 Another study showed diminished blastogenic-and skin test responses to M. leprae antigens among HIV-positive tuberculoid leprosy patients, consistent with the possibility of increased leprosy risk. 12 The controversial nature of the reported studies suggests that subtle, undetected factors could be disguising the true relationship between AIDS and leprosy in the reported epidemiological studies. Our observations are based on direct disease signs and immunologic determinations in a controlled experimental model system, 4 , 5 whereas observations in humans are correlative, based on the presence or absence of antibody to HIV in identifiable leprosy patients. 9 -14 In the present study, we have utilized this model to further study the possibility of clinical and immunologic interactions between SIV and M. leprae. The results are consistent with increased M. leprae persistence and probable enhanced leprosy suscept ibility due to impaired immune responses to M. leprae in SIV -coinfected RM compared to those infected with M. leprae alone.
Methods

ANIMALS
Rhesus monkeys (Macaca mulatta), 3-4 years old, were born and reared at the Tulane Regional Primate Research Center. Eight RM which had been inoculated with SIV 8-10 months previously and four normal control RM were inoculated with M. leprae. At the time of M. leprae inoculation, 3 of the 8 SIV-inoculated RM were showing acute AIDS symptoms (L156, 13 14, and 15 10, Table 1 ); the remaining 5 RM were negative for AIDS symptoms. All RM were clinically and immunologically followed longitudinally after M. leprae inoculation.
INOCULA TIONS
An armadillo previously inoculated with M. leprae taken from a sooty mangabey money (SMM) developed progressive, disseminated lepromatous leprosy and was humanely killed. t Histopath DX = histopathological diagnosis (PB, paucibacillary; MB, multibacillary) at necropsy (except for 1798, which remains alive).
:t: Days PI, number of days after M. leprae-inoculation that the animal was euthanized (except for 1798-which first was observed to have AFB-positive nasal secretions and inoculation site biopsies on day 146 and continues nasal-positive on day 1137).
§ AIDS status at time of necropsy (except 1798 which developed AIDS symptoms approximately 3 years post M. leprae inoculation and is alive).
'II RM 13 14, 15 10 and 1798 had nasal secretions strongly positive for acid-fast bacilli (AFB), indicating systemic dissemination of leprosy. ** 15 10 was euthanized on day 160 PI due to complications secondary to an unrelated condition; 15 10 had AFB at dermal sites of inoculation with MB histopathology and had AFB-positive nasal secretions, but was had no evidence of AIDS at necropsy.
M. leprae was harvested from its spleen. All armadillo procedures, including inoculation, husbandry and organ harvests were performed by Dr Richard B Truman at the Research Branch, National Hansen's Disease Center, Baton Rouge, LA, USA. Contaminating SIV from SMM does not cause detectable AIDS symptoms in and does not survive passage through armadillos (Gormus, BJ, Murphey-Corb, M., unpublished observations). The spleen was obtained aseptically, minced and homogenized in cold phosphate buffered saline using a Dounce homogenizer with a 40 Ml mortar and Teflon pestle (Wheaton Scientific, Millville, NJ, USA), passed through gauze and centrifuged at 200 x G for 5 min at 4°C. The AFB in the supernatant were counted and morphologic indices (MI) determined by the method of Shepard & McCrae. 15 RM were inoculated with M. leprae suspensions by combined intradermal (lD) and intravenous (IV) routes using 2 ID sites per ear, the tip of the nose, lateral forearms and lateral calves. IV inoculations were made via the saphenous vein. The inoculum contained 2·24 x 10 8 AFBIMI with an MI of 7%. A total of 1·5 MI (3-4 x 10 8 AFB)
was inoculated by the ID route and 2·0 MI (4'5 x 10 8 AFB) by the IV route, for a total of Animals were observed twice daily and examined in detail monthly or more frequently, depending on the status of the animal. Clinical aspects of AIDS and leprosy were recorded at each time of observation. The Ridley-Jopling system was used to classify leprosy histo pathologically, 1 7 with the exception that classification at the paucibacillary (PB) end of the spectrum differs slightly in RM from humans, as previously noted (Gormus BJ, et ai, submitted for publication). For purposes of this report, however, leprosy will be described as multibacillary (MB) or PB . MB will include borderline to lepromatous forms on the Ridley Jopling spectrum; 1 7 PB includes tuberculoid to borderline tuberculoid forms. AIDS was diagnosed as previously described. 5 -8
ELISA
The assays were performed as previously reported. 
BLASTOGENESIS
Heparinized blood was used to prepare buffy coats which were centrifuged on Ficolll Hypaque, washed and suspended in RPMI-I640 containing 20% heat-inactivated human AB serum (HuABS), glutamine and penicillin/streptomycin. The mononuclear cell (MNC) fraction was used at 2 x 10 6 IMI for in vitro blastogenesis studies with or without 100 JLglMl of ML sonicate antigen (MLS) or 1 or 10 JLglMl of Concanavalin A (ConA). U-bottom 96-well micro titer plates were used. Two x 10 5 MNC per well were incubated at 37°C in 5% CO 2 in triplicate for 5 days with stimulant or media prior to pulsing for 18 hr with 1 JLci of 3 H_ thymidine/well. Thereafter, cells were washed and harvested on a cell-harvester and quantified by scintillation counting. Results are presented as means +/-one standard deviation (SD) of replicate absolute cpm.
PERIPHERAL BLOOD LYMPHOCYTE (PB L) SUBSETS
Whole EDT A blood was obtained longitudinally, stained with mouse anti-human monoclonal antibodies and examined by flow cytometry, as previously reported. 1 9 , 20 Monoclonal antibodies with the following specificities were used: CD4, CD8, CD2, CD20 and CD29. CD2 and CD20 subsets were chosen to quantify the total T-and B-cells, respectively; CD4 and CD8 were examined to determine the T-helper and T-suppressor percentages, respectively, since these cells are known to be involved in responses to M. leprae antigens; and the CD4+CD29+ subset was monitored because this group contains the T-helper inducer and T-memory cells and is known to be progressively diminished in RM with advancing AIDS. 1 9 Results are presented as the group mean % of total PBL at different time points + or -1 standard error of the mean (SEM) vs time.
SIV ANTIGENEMIA ASSAY SIV antigenemia was detected using a commercially available enzyme-linked immunoassay kit specific for the p26 antigen of SIV (Coulter Immunology, Hialeah, FL), as previously reported. 2 o The cut-off point for antigenemia was an OD value <0·03. Data from individual RM are plotted as NglMl of blood calculated from a standard curve.
STATISTICAL ANALYSES
A statistical package for Macintosh computer was utilized for data analysis. Mancova was used where possible to compare longitudinally-determined lymphocyte subset percentage changes with time after M. Zeprae inoculation in RM groups infected with M. Zeprae alone or together with SIV. Mancova was made difficult for longitudinal comparisons over an extended period, however, due to the deaths of some RM at various time points, resulting in the complete elimination by the statistic of all prior time points for that animal (i.e. total loss of one value of N at all time points) for each death that occurred prior to the end of the study. Therefore, the unpaired Student' s t-test was additionally used for PBL subset data analysis to statistically compared group averages. The t-test was also used for analysis of blastogenic data.
Results
CLINICAL
Seven of the 8 SIV IML coinfected group were euthanized due to AIDS or, in the case of animal 15 10 due to unrelated causes, within 270 days postinoculation (PI) with ML ( 
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SIV ANTIGENEMIA AND ANTIBODY RESPONSES TO SIV GP120 ENVELOPE ANTIGEN
Over a period including pre-SIV inoculation (-232 to -300 days relative to M. leprae inoculation), 8-10 months post-SIV/pre-M. leprae inoculation and up to death or 235 days post-M. leprae inoculation, anti-Gp l20 responses were significant in all SIV-inoculated RM after the appearance of SIV antigenemia (Figure 2(a) ). Only the I :50 dilution-data are shown. These antibody responses were maintained until death or, in 13 14 and J798, up to 235 days post-M. leprae inoculation, the last time point studied. The first detectable antigenemia peak appeared within approximately 2 weeks post-SIV inoculation, but disappeared thereafter, in all 8 SIV infected RM (Figure 2(a) ). After M. leprae inoculatiion, SIV antigenemia was again detectable in RM L156, 1877 (minimal, but above the cut-off point) and J703 (Figure 2(a) , see asterisks). There was, of course, no SlY antigenemia or anti-Gp l20 response in control sera from M. leprae-only inoculated animals ( Figure 2(b) ).
BLASTOGENESIS
There was a statistically significant decrease in ConA responses (p = ·0015, t-test) in the SIV/M . leprae coinfected group, compared to a significant increase (p = 0'01) in ConA responses in the M. leprae-only inoculated group pre-vs 15 weeks post-M. leprae inoculation (Figure 3 ). There were no statistically significant responses to MLS in the ISV/M. leprae coinfected group before or 15 weeks after M. leprae inoculation except for the long-term survivor, J798, which gave a significant response to MLS 15 weeks post-M. leprae inocula tion ( Figure 3 ). MLS responses increased significantly (p = 0·02) in the M. leprae-only infected control group 15 weeks PI compared to preinoculation responses ( Figure 3 ).
LYMPHOCYTE SUBSETS
Within the first 300 days post-M. leprae inoculation, the following statistically significant changes were observed in the lymphocyte subsets examined: 1, an increase in the % CD2+ subset at 13 and 26 days (p = 0·009 & p = 0·04, respectively, t-test) post-M. leprae inoculation in the M. leprae-only inoculated (control) group (Figure 4 14 !.
• ; : I 4(c» . There was no change in the % CD8+ subset in the SIVIM. leprae coinfected vs an increase in this subset in the M. leprae-only inoculated group during the 62 days post M. leprae inoculation period (Figure 4 (d» ; this difference was not significant. There was a transient increase in CD20+ B-cells in the SIVIM. leprae coinfected group and a decrease of longer duration in CD20+ B-cells in the M. leprae-only inoculated group early after M. leprae inoculation, but this difference was also not statistically significant.
Discussion
The clinical results are consistent with our previous suggestions derived from experimental studies in RM that SIVIML coinfection enhances the susceptibility of RM to leprosy. 4 Seven of 8 SIVIM. leprae coinfected RM developed signs of leprosy or M. leprae persistence that were sustained until necropsy or, in one surviving case, to date 37 months post-M. leprae inoculation. Control RM, inoculated with M. leprae only cleared APB from dermal M. leprae inoculation sites by 27 or 63 days PI and have remained AFB-negative to date, 1137 days after M. leprae inoculation. We have previously observed that the appearance of M. leprae in nasal secretions is an early indication of systemic dissemination of clinical leprosy in experimentally inoculated monkeys. 18 Three of the 8 coinfected animals studied herein developed strongly AFB positive nasal secretions. Thus, the clinical data show an increased susceptibility towards persistence of M. leprae at dermal sites and an increased tendency to disseminate systemically in SIV coinfected compared to M. leprae-only infected animals.
Only one (15 10) of the 8 coinfected RM failed to develop clinical AIDS, but it was prematurely sacrificed due to an unrelated medical condition 160 days post-M. leprae inoculation. This animal had MB leprosy at an inoculation site and AFB -positive nasal secretions at necropsy. Six of the 7 AIDS-positive RM were necropsied due to terminal AIDS within 270 days post-M. leprae inoculation.
The 7th AIDS-positive animal, the long-term survivor, remains alive with disseminated MB leprosy. The long term survivor has strongly AFB-positive nasal secretions first observed by 160 days PI, but has continued to show AFB-negative dermal biopsies. This RM displayed essentially normal immune responsiveness. The exact reason for it' s uniqueness among the 8 coinfected RM is not known with certainty, but approximately 25% or RM experimentally infected with SIVB 670 fall into this AIDS-slow progression category (M. Murphey-Corb, unpublished observations). To our knowledge, this RM had never been previously exposed to M. leprae. It is important to note that this latter RM, #1798, and 2 other animals with AFB positive nasal secretions (13 14 The totally suppressed antibody responses to M. leprae-specific PGL-I cell wall antigen in 7 of 8 SIVIML coinfected RM compared to significant responses in M. leprae-only infected RM indicates that SIV abrogates primary antibody responses to this M. leprae antigen in all of the coinfected RM except the long term survivor (1798). The impaired antibody responses appear to effect the primary, and not the secondary or memory compartment, as suggested by the long-tenn presence of undiminished levels of anti-Gp l20 antibodies beyond the known half-life of immunoglobulins. Unfortunately, in the design of this study we did not anticipate the need for testing for responsiveness to unrelated antigens. This will be included in a future protocol.
Since the CD4+CD29+ subset contains helper-inducer and memory cells, it is conceivable that the M. leprae-specific immunologic impainnents may be associated with a pre-existing SIV-induced diminution of CD4+ and CD4+CD29+ T-cell subsets that is observed in most SIV-positive RM. 4 •1 9 , 2 0 The longitudinal PBL subset data indicate that, in SIV-positive RM, an early additional small, but statistically significant loss occurs in the CD4+CD29+ T-cell subset after M. leprae inoculation. The CD4+CD29+ subset deficit is known to correlate with rapid AIDS progression in RM (19), but further investigations will be required to determine whether this specific defect contributes to the enhanced susceptibility to M. leprae persistence and dissemination in coinfected RM.
Previously, we reported that RM inadvertently coinoculated with SIV simultaneously with M. leprae (prior to our knowledge that captive sooty mangabey monkeys, the source of the M. leprae inoculum, carry SIV asymptomatically) developed AIDS and leprosy and produced anti-PGL-I IgG antibody responses. 4 This is in contrast to the observations herein which revealed a complete inhibition of anti-PGL-I responses in 7 of 8 coinfected RM. A probable explanation for this discrepancy is twofold: 1, RM in the fonner study most likely received extremely low doses of SlY, inadvertently present as a contaminate in the M. leprae inoculum, compared to known lethal doses of cryopreserved SIV experimentally given in the present study; and 2, RM in the fonner study 4 were simultaneously infected with ML and SlY, whereas in the present study, RM were inoculated with SIV 8-10 months prior to M. leprae. Surprisingly, the clinical results of an additional study now in progress suggest that lethality is greater when SIV is given to RM simultaneously with M. leprae compared to SIV being given prior to M. leprae (Gonnus, BJ et aI, unpublished observations). Thus, it appears that the effect of coinfection with the two agents depends, among other things, on the doses given and the relative timing of the two infections. Experiments are planned to examine in greater detail the effects of relative timing of the 2 infections, including M. leprae infection soon after SIV inoculation. Studies are now in progress to examine the effects of SIV infection on leprosy reactivation in leprosy-quiescent M. leprae infected animals. The present data do not pennit us to explain with certainty why studies from the field fail to consistently detect an interaction between HIV and leprosy among human populations. The re sults suggest that susceptibility to clinical leprosy is enhanced in leprosy cases coinfected with the AIDS virus. It is difficult to absolutely prove this point due to the generally observed rapid lethality of the combined infections observed in RM.
The rapid lethality observed in most SIVIM. leprae coinfected RM is a possible partial explanation for the failure of field studies to consistently detect an interaction between HIV and M. leprae. If a significant percentage of HIV -coinfected leprosy patients with a secondary HIV infection were to succumb early, prior to leprosy recognition (and/or, perhaps, prior to recognition of AIDS), it could conceal the true effect of coinfection.
If it is hypothesized that visible leprosy clinical symptoms are largely the result of the immune response to M. leprae, another possible explanation, suggested by the present immunologic results, is that clinical symptoms fail to appear in coinfected cases due to the AIDS virus-induced suppression of the immune response to M. leprae antigens. If so, coinfected patients would tend to be systematically excluded from study populations. Taken together, our clinical and immunologic data present a strong argument that some systematic factor is being overlooked in field studies that have failed to find an association between AIDS and increased leprosy susceptibility.
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The specific effect of SIV on the course of M. leprae infection is dependent on several variables and is deserving of continued study. The possible implications of our observations for future resurgence of increased numbers of leprosy cases worldwide would seem to demand a very through investigation of and resolution to questions we have raised. Our studies are direct, not depending on epidemiological correlations, using a nonhuman primate model that is phylogenetic ally very similar to humans to reach our conclusions. The results imply that it may not be readily possible to determine the true epidemiologic relationship between HIV and M. lep rae infections by studying human populations. Our conclusions are disturbing because they continue to portend a possible drastic increase in future leprosy cases in AIDSlleprosy-endemic areas without detection before it is too late to take effective preventative measures.
